Human phase‐I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl‐CBMEGACLONE, Cumyl‐NBMEGACLONE, and Cumyl‐NBMINACA
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Arianna Giorgetti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Cannabinoids, Cannabinoid Receptor Agonists, Indazoles, Designer Drugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Synthetic cannabinoid receptor agonists (SCRAs) continue to show high prevalence on the new psychoactive substances drug market. Around 2019–2020, new SCRAs bearing a cumyl moiety emerged: Cumyl‐CBMEGACLONE and Cumyl‐NBMEGACLONE, carrying a cyclobutyl methyl (CBM) and a norbornyl methyl moiety (NBM) attached to the γ‐carbolinone core. These were followed by Cumyl‐NBMINACA, the indazole carboxamide analog of Cumyl‐NBMEGACLONE. The study aimed at evaluating the human phase‐I metabolism of these compounds and at identifying suitable urinary markers to prove their consumption. After enzymatic hydrolysis, 14 authentic urine samples (eight for Cumyl‐CBMEGACLONE, four for Cumyl‐NBMEGACLONE, and two for Cumyl‐NBMINACA) were analyzed by liquid chromatography–quadrupole time‐of‐flight mass spectrometry. Results were compared with in vitro metabolites generated by pooled human liver microsomes incubation. Fifteen human phase‐I metabolites were identified for Cumyl‐CBMEGACLONE, nine for Cumyl‐NBMEGACLONE, and thirteen for Cumyl‐NBMINACA. The main in vivo metabolites were built by monohydroxylation, dihydroxylation, or trihydroxylation. The following urinary biomarkers are suggested for detecting the consumption of the investigated SCRAs: products of monohydroxylation at the CBM and at the core for Cumyl‐CBMEGACLONE; two products of monohydroxylation at the norbonyl methyl tail for Cumyl‐NBMEGACLONE; and metabolites built by dihydroxylation at the NBM substructure and by an additional hydroxylation at the cumyl moiety for Cumyl‐NBMINACA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Bologna, Italy.
- Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Federal Criminal Police Office, Forensic Science Institute, Wiesbaden, Germany.
ORCID-Profile: Benedikt Pulver, Volker Auwärter
Zitieren
APA
Giorgetti, A., Brunetti, P., Haschimi, B., Pulver, B., Pascali, J. P., Riedel, J., & Auwärter, V. (2025). Human phase‐I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl‐CBMEGACLONE, Cumyl‐NBMEGACLONE, and Cumyl‐NBMINACA. Drug Testing and Analysis. https://doi.org/10.1002/dta.3791
Vancouver
Giorgetti A, Brunetti P, Haschimi B, Pulver B, Pascali JP, Riedel J, et al. Human phase‐I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl‐CBMEGACLONE, Cumyl‐NBMEGACLONE, and Cumyl‐NBMINACA. Drug Testing and Analysis. 2025. doi:10.1002/dta.3791
BibTeX
@article{Giorgetti2025,
author = {Giorgetti, Arianna and Brunetti, Pietro and Haschimi, Belal and Pulver, Benedikt and Pascali, Jennifer Paola and Riedel, Jan and Auwärter, Volker},
title = {Human phase‐I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl‐CBMEGACLONE, Cumyl‐NBMEGACLONE, and Cumyl‐NBMINACA},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3791}
}
EUVIMED